

Target Market Determination (TMD)

Issuer:	Bio-Gene Technology Ltd (ABN 32 071 735 950) (the Company ; ASX: BGT)
Product:	SPP Option (exercise price of 3.5 cents per option, expiry date of 15 October 2027) (SPP Option)
Effective Date:	2 June 2026

This target market determination (**TMD**) has been prepared by the Company in relation to an offer to issue the SPP Options by the Company to the Eligible Shareholders under the Prospectus. A copy of the Prospectus is available on the Company's website: bio-gene.com.au. Capitalised terms which are used in this TMD have the same meanings as in the Prospectus unless the context requires otherwise.

The offer of SPP Options will be made under, or accompanied by, a copy of the Prospectus. Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their professional adviser if they have any questions regarding the contents of the Prospectus. The issue of the SPP Options is subject to shareholder approval.

Eligible Shareholders who apply for and are issued with shares in the Company under the Company's offer of shares under its Share Purchase Plan (**SPP**) will (subject to shareholder approval) be issued with one SPP Option for every two fully paid ordinary shares that are issued to them under the SPP.

There is no cooling off period in respect of the offer and issue of the SPP Options. This TMD is not a disclosure document for the purposes of the *Corporations Act 2001* (Cth), and therefore has not been lodged, and does not require lodgement, with the Australian Securities and Investments Commission (**ASIC**) nor does it contain a full summary of the terms and conditions of the SPP Options.

This TMD does not take into account what you currently have, or what you want and need, for your financial future. It is important for you to consider these matters and read the Prospectus before you make an investment decision. The Company is not licensed to provide financial product advice in relation to the SPP Options.

1. Target Market Summary

This financial product is designed for investors who:

Participate in the Company's Share Purchase Plan (**SPP**).

- Seek **potential leverage** through options while maintaining exposure to Bio-Gene Technology Ltd.
- Understand **options-related risks**, including expiry conditions and dilution effects.
- Have a **medium-to-high risk tolerance**, given agricultural technology sector volatility.
- Intend to use the SPP Options for **capital appreciation or strategic portfolio positioning**.

2. Distribution Conditions

This product should be distributed through:

- **Licensed financial advisers** who assess suitability for investors.
- **Online trading platforms** with adequate risk disclosures.
- **Direct issuer placements** following investor suitability assessments.

3. Risk and Investment Suitability

Investors should be aware of risks, including:

- **General risks** due to nature of the business
- **Liquidity risk**, as the Company shares may be thinly traded.
- **Dividend risk**, as the Company does not currently pay dividends.
- **Regulatory risk**, including changes in bio-insecticides approvals.
- **Funding risk**, The Company's ability to effectively implement its business strategy over time may depend in part on its ability to raise additional funds.

4. Review Triggers

The SPP Options are being offered for a limited offer period set out in the Prospectus, after the conclusion of which SPP Options will no longer be available for investment by way of issue. It follows that the TMD will only apply in the period between the commencement of the offer of the SPP Options and end at the time that the SPP Options

are issued following the close of the offer of the SPP Options (the **SPP Options Offer Period**).

To allow the Company to determine whether circumstances exist that indicate this TMD is no longer appropriate to the SPP Options and should be reviewed, the following review triggers apply for the SPP Options Offer Period:

- (a) a new offer of SPP Options that requires preparation of a disclosure document is made after completion of the SPP Options Offer Period;
- (b) any event or circumstance that would materially change a factor taken into account in making this TMD;
- (c) the existence of a significant dealing of the SPP Options that is not consistent with this TMD;
- (d) ASIC raises concerns with the Company regarding the adequacy of the design or distribution of the SPP Options or this TMD; and
- (e) material changes to the regulatory environment that applies to an investment in the SPP Options.

5. Review Period

If a review trigger occurs during the SPP Options Offer Period, the Company will undertake a review of the TMD in light of the review trigger. The Company will otherwise complete a review of the TMD immediately prior to the issue of SPP Options under the Prospectus.

6. Reporting Obligations

Distributors must report:

- Significant dealings outside the target market.
- Complaints related to the financial product.
- Any regulatory concerns affecting investor suitability.

7. Contact Details

Contact details in respect of this TMD for the Company are:

Company Secretary: Drew Speedy

Email: cfo@bio-gene.com.au